David Ferguson

Prof. David Ferguson

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
FPFrancesc Puig-Basagoiti
Francesc Puig-Basagoiti
MTMark Tilgner
Mark Tilgner
BFBrett M. Forshey
Brett M. Forshey
SPSean M. Philpott
Sean M. Philpott
NENoel G. Espina
Noel G. Espina
PSPei-Yong Shi
Pei-Yong Shi
Triaryl pyrazoline {[5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro-pyrazol-1-yl]-phenyl-methanone} inhibits flavivirus infection in cell culture. The inhibitor was identified through high-throughput screening of a compound library using a luciferase-expressing West Nile (WN) virus infection assay. The compound inhibited an epidemic strain of WN virus without detectable cytotoxicity (a 50% effective concentration of 28 μM and a compound concentration of ≥300 μM required to reduce 50% cell viability). Besides WN virus, the compound also inhibited other flaviviruses (dengue, yellow fever, and St. Louis encephalitis viruses), an alphavirus (Western equine encephalitis virus), a coronavirus (mouse hepatitis virus), and a rhabdovirus (vesicular stomatitis virus). However, the compound did not suppress an orthomyxovirus (influenza virus) or a retrovirus (human immunodeficiency virus type 1). Mode-of-action analyses in WN virus showed that the compound did not inhibit viral entry or virion assembly but specifically suppressed viral RNA synthesis. To examine the mechanism of inhibition of dengue virus, we developed two replicon systems for dengue type 1 virus: (i) a stable cell line that harbored replicons containing a luciferase reporter and a neomycin phosphotransferase selection marker and (ii) a luciferase-expressing replicon that could differentiate between viral translation and RNA replication. Analyses of the compound in the dengue type 1 virus replicon systems showed that it weakly suppressed viral translation but significantly inhibited viral RNA synthesis. Overall, the results demonstrate that triaryl pyrazoline exerts a broad spectrum of antiflavivirus activity through potent inhibition of viral RNA replication. This novel inhibitor could be developed for potential treatment of flavivirus infection.

29 December 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JGJohn R. Goodell
John R. Goodell
AOAndrei V. Ougolkov
Andrei V. Ougolkov
HHHiroshi Hiasa
Hiroshi Hiasa
HKHarneet Kaur
Harneet Kaur
RRRory Remmel
Rory Remmel
DFDavid Ferguson
David Ferguson

18 October 2018 in Nanoscale
Verified
Journal Article
Closed access
PDF file
HKHyunjoon Kim
Hyunjoon Kim
DSDrishti Sehgal
Drishti Sehgal
TKTamara A. Kucaba
Tamara A. Kucaba
DFDavid Ferguson
David Ferguson
TGThomas Griffith
Thomas Griffith
Jayanth PanyamJayanth Panyam
Jayanth Panyam
Synthetic imidazoquinoline-based toll-like receptor (TLR) 7/8 bi-specific agonists are promising vaccine adjuvants that can induce maturation of dendritic cells (DCs) and activate them to secrete pro-inflammatory cytokines. However, in vivo efficacy of these small molecule agonists is often hampered by their fast clearance from the injection site, limiting their use to topical treatments. In this study, we investigated the use of acidic pH-responsive poly(lactide-co-glycolide) (PLGA) nanoparticles for endo–lysosome specific release of 522, a novel TLR7/8 agonist. Bicarbonate salt was incorporated into the new formulation to generate carbon dioxide (CO2) gas at acidic pH, which can disrupt the polymer shell to rapidly release the payload. Compared to conventional PLGA nanoparticles, the pH responsive formulation resulted in 33-fold higher loading of 522. The new formulation demonstrated acid-responsive CO2 gas generation and drug release. The acid-responsive formulation increased the in vitro expression of co-stimulatory molecules on DCs and improved antigen-presentation via MHC I, both of which are essential for CD8 T cell priming. In vivo studies showed that the pH-responsive formulation elicited stronger antigen-specific CD8 T cell and natural killer (NK) cell responses than conventional PLGA nanoparticles, resulting in enhanced anticancer efficacy in a murine melanoma tumor model. Our results suggest that acidic-pH responsive, gas-generating nanoparticles are an efficient TLR7/8 agonist delivery platform for cancer immunotherapy.

1 March 2006 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
BKBrian E. Kane
Brian E. Kane
BSBengt Svensson
Bengt Svensson
DFDavid Ferguson
David Ferguson

10 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CSCharles E. Schiaffo
Charles E. Schiaffo
CSCe Shi
Ce Shi
ZXZhengming Xiong
Zhengming Xiong
MOMichael Olin
Michael Olin
JOJohn R. Ohlfest
John R. Ohlfest
DFDavid Ferguson
David Ferguson

24 May 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSShiv Sharma
Shiv Sharma
RJRobert M. Jones
Robert M. Jones
TMThomas G. Metzger
Thomas G. Metzger
DFDavid Ferguson
David Ferguson
PPPhilip S. Portoghese
Philip S. Portoghese